MUHU Health
EnglishObtenga una evaluación gratuita

Cuéntenos cómo su condición limita su vida diaria

Vivir con inflamación puede volver impredecibles los planes diarios. Empiece por el diagnóstico de su especialista, el cambio que le preocupa ahora y la actividad o comodidad que espera recuperar.

Ilustración en acuarela de la vida cotidiana en la región montañosa de Colombia

Su atención actual también es parte del panorama.

Cuéntele a nuestro equipo sobre su especialista, los brotes recientes, el seguimiento y los medicamentos actuales, incluidos los tratamientos biológicos o inmunosupresores. Estos detalles orientan la evaluación y nos ayudan a comprender cómo encajaría cualquier atención propuesta junto con su atención especializada actual.

Incluya detalles sobre su atención actual

Su especialista y equipo de atención
Brotes y cambios recientes
Resultados de seguimiento
Sus medicamentos actuales, incluidos biológicos o inmunosupresores

Inquietudes que nos comparten:

Artritis reumatoide

Una enfermedad inflamatoria autoinmune que afecta principalmente las articulaciones y puede involucrar otras partes del cuerpo.

Lupus eritematoso sistémico (LES)

Comparta la evaluación de su especialista sobre el lupus eritematoso sistémico, los cambios recientes, sus medicamentos y la pregunta que desea revisar.

Psoriasis

Una afección mediada por el sistema inmunitario que suele afectar la piel y también puede afectar las articulaciones.

Enfermedad de injerto contra huésped

Una complicación tras un trasplante de células madre o médula ósea de donante, en la que las células inmunitarias del donante afectan tejidos del receptor.

Todos los tratamientos que ofrecemos están respaldados por estudios clínicos.Consulte la investigación

Autoinmunidad, intestino e inflamación

97 estudios
  1. Immunomodulatory effects of extracellular vesicles from mesenchymal stromal cells: Implication for therapeutic approach in autoimmune diseases. (2024)
  2. Intestinal Inflammation and Regeneration-Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease. (2024)
  3. Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease. (2022)
  4. Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges. (2023)
  5. Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy. (2023)
  6. A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis. (2022)
  7. Efficacy and safety of mesenchymal stem cells in the treatment of perianal fistulas in Crohn's disease: a meta-analysis of randomized controlled trials. (2023)
  8. Mesenchymal Stem Cells Versus Placebo for Perianal Fistulizing Crohn's Disease: A Systemic Review and Meta-Analysis. (2023)
  9. Exosomes derived from mesenchymal stem cells containing berberine for ulcerative colitis therapy. (2024)
  10. Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease. (2024)
  11. Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study. (2024)
  12. Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations. (2024)
  13. Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis. (2024)
  14. Localized Administration of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Refractory Perianal Fistula in Crohn's Disease Patients: A Phase II Clinical Trial. (2024)
  15. Safety and efficacy of stem cell therapy for Crohn's disease: An umbrella review of systematic reviews. (2024)
  16. Efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis of randomized controlled trials. (2024)
  17. Optimizing Treatment Outcomes in Crohn's Disease: A Comprehensive Systematic Review and Meta-Analysis of Regenerative Therapies with Emphasis on Platelet-Rich Plasma. (2024)
  18. Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn's Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study). (2024)
  19. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. (2024)
  20. Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease. (2025)
  21. Perianal fistulizing Crohn's disease: Mechanisms and treatment options focusing on cellular therapy. (2025)
  22. Allogenic stem cells for Crohn's anal fistulas: Treating early improves the deep remission rate. (2023)
  23. Safety and Potential Efficacy of Expanded Umbilical Cord-Derived Mesenchymal Stromal Cells in Luminal Ulcerative Colitis Patients. (2024)
  24. Mesenchymal Stromal Cells: New Generation Treatment of Inflammatory Bowel Disease. (2024)
  25. Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. (2025)
  26. The therapeutic efficacy of adipose mesenchymal stem cell-derived microvesicles versus infliximab in a dextran sodium sulfate induced ulcerative colitis rat model. (2024)
  27. Hematopoietic Stem Cell Aging and Leukemia Transformation. (2023)
  28. International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges. (2024)
  29. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. (2023)
  30. Efficacy of off-the-shelf bone marrow mesenchymal stem cells for pediatric steroid-refractory acute graft-versus-host disease. (2023)
  31. Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease. (2023)
  32. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease. (2023)
  33. Are mesenchymal stem cells still effective in acute GvHD management? Transfus Apher Sci. (2024)
  34. Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up. (2024)
  35. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study. (2024)
  36. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. (2024)
  37. Cellular therapies for the prevention and treatment of acute graft-versus-host disease. (2025)
  38. Emerging Role and Mechanism of Mesenchymal Stem Cells-Derived Extracellular Vesicles in Rheumatic Disease. (2024)
  39. Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases. (2025)
  40. Application of cell therapy in rheumatoid Arthritis: Focusing on the immunomodulatory strategies of Mesenchymal stem cells. (2025)
  41. Management of Rheumatoid Arthritis: Possibilities and Challenges of Mesenchymal Stromal/Stem Cell-Based Therapies. (2023)
  42. The Effects of Mesenchymal Stem Cells on the Gene Expression of TGF-beta and IFN-gamma in Patients with Rheumatoid Arthritis. (2023)
  43. Cell-based therapies for the treatment of rheumatoid arthritis. (2023)
  44. Rheumatoid arthritis: the old issue, the new therapeutic approach. (2023)
  45. The effects of mesenchymal stem cells-derived exosomes in rheumatoid arthritis: a review. (2023)
  46. Mesenchymal Stem/Stromal Cell-Based Therapies in Systemic Rheumatic Disease: From Challenges to New Approaches for Overcoming Restrictions. (2023)
  47. The Role of Extracellular Vesicles in the Pathogenesis and Treatment of Rheumatoid Arthritis and Osteoarthritis. (2023)
  48. Extracellular vesicles: immunomodulation, diagnosis, and promising therapeutic roles for rheumatoid arthritis. (2024)
  49. The Role of Mesenchymal Stromal Cells in the Treatment of Rheumatoid Arthritis. (2024)
  50. Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy. (2024)
  51. A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis. (2024)
  52. Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis. (2024)
  53. Breaking barriers: advancing cellular therapies in autoimmune disease management. (2024)
  54. Extracellular vesicles as therapeutic agents in rheumatoid arthritis: a systematic review of current evidence. (2025)
  55. Combination treatment with interferon-γ may be a potential strategy to improve the efficacy of cytotherapy for rheumatoid arthritis: A network meta-analysis. (2024)
  56. Mesenchymal stem cell transplantation may be able to induce immunological tolerance in systemic lupus erythematosus. (2024)
  57. Current cell therapies for systemic lupus erythematosus. (2024)
  58. Umbilical Cord Mesenchymal Stem Cell Secretome: A Potential Regulator of B Cells in Systemic Lupus Erythematosus. (2024)
  59. Hypoxic mesenchymal stem cells (MSCS)-induced interleukin (IL)-10 alleviate systemic lupus erythematosus (SLE) infl ammation through inhibiting interferon (IFN)-gamma production. (2024)
  60. Potential Therapeutic Application and Mechanism of Action of Stem Cell-Derived Extracellular Vesicles (EVs) in Systemic Lupus Erythematosus (SLE). (2024)
  61. Mesenchymal stem cells for immune modulation in systemic lupus erythematosus: From bench research to clinical applications. (2024)
  62. Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus via Glucose Metabolism of CD4+T Cells. (2025)
  63. Harnessing miR-16-5p-Loaded Exosomes from Adipose-Derived Stem Cells to Restore Immune Homeostasis in SLE Patients. (2025)
  64. Efficacy of Mesenchymal Stem Cell Therapy on Lupus Nephritis and Renal Function in Systemic Lupus Erythematosus: A Meta-Analysis. (2023)
  65. Stem cell-based therapy for systemic lupus erythematous. (2024)
  66. Targeted Cellular Treatment of Systemic Lupus Erythematosus. (2025)
  67. Umbilical-Cord-Derived Mesenchymal Stromal Cells Modulate 26 Out of 41 T Cell Subsets from Systemic Sclerosis Patients. (2023)
  68. Potential angiogenic, immunomodulatory, and antifibrotic effects of mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis. (2023)
  69. Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized controlled trials. (2024)
  70. Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents. (2024)
  71. Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study. (2024)
  72. Improvement in Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis. (2025)
  73. Guidance for stem cell therapy for juvenile systemic sclerosis patients. (2025)
  74. Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study. (2025)
  75. Cell-free regenerative medicine: identifying the best source of mesenchymal stem cells for skin therapy in Systemic Sclerosis. (2025)
  76. Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies. (2025)
  77. The effect of hematopoietic stem cell transplantation on cardiac mechanics in systemic sclerosis. (2025)
  78. Targeted Therapy for Severe Sjogren's Syndrome: A Focus on Mesenchymal Stem Cells. (2024)
  79. miRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental Sjögren's syndrome by suppressing Th17 cells via targeting RORC/IL-17A signaling axis. (2025)
  80. Regenerative fibroblasts derived from autologous skin tissue for the treatment of Sjögren's syndrome: a case report. (2025)
  81. Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sjögren's syndrome: A randomized clinical trial. (2024)
  82. Diagnostic and therapeutic potentials of extracellular vesicles for primary Sjögren's Syndrome: A review. (2024)
  83. A review of the roles of exosomes in salivary gland diseases with an emphasis on primary Sjögren's syndrome. (2025)
  84. The use of stem cells in treating xerostomia: a systematic review. (2024)
  85. Comparative Analysis of the Therapeutic Effects of Fresh and Cryopreserved Human Umbilical Cord Derived Mesenchymal Stem Cells in the Treatment of Psoriasis. (2023)
  86. Subcutaneous Injection of Allogeneic Adipose-Derived Mesenchymal Stromal Cells in Psoriasis Plaques: Clinical Trial Phase I. (2023)
  87. Psoriasis: The Versatility of Mesenchymal Stem Cell and Exosome Therapies. (2024)
  88. Efficient Treatment of Psoriasis Using Conditioned Media from Mesenchymal Stem Cell Spheroids Cultured to Produce Transforming Growth Factor-β1-Enriched Small-Sized Extracellular Vesicles. (2024)
  89. The safety and efficacy of adipose tissue-derived exosomes in treating mild to moderate plaque psoriasis: A clinical study. (2024)
  90. Expert Consensus on the Application of Stem Cells in Psoriasis Research and Clinical Trials. (2024)
  91. A phase 1, open-label study to determine safety and tolerability of the topical application of mesenchymal stem/stromal cell (MSC) exosome ointment to treat psoriasis in healthy volunteers. (2025)
  92. Mesenchymal stromal cells and their small extracellular vesicles in allergic diseases: from immunomodulation to therapy. (2023)
  93. Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis. (2023)
  94. Phase 1/2 trials of human bone marrow-derived clonal mesenchymal stem cells for treatment of adults with moderate to severe atopic dermatitis. (2024)
  95. Therapeutic Potential and Mechanisms of Mesenchymal Stem Cell and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Atopic Dermatitis. (2024)
  96. The Role of Exosomes in Medical Dermatology: Literature Review and Update. (2025)
  97. Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Management of Atopic Dermatitis: A Scoping Review of Therapeutic Opportunities and Challenges. (2025)

Comprenda las opciones y el precio completo

Nuestro equipo médico revisa sus antecedentes junto con su atención actual. Si se propone un tratamiento, recibirá un plan que identifique el procedimiento, las citas, el seguimiento y el costo total antes de tomar decisiones de viaje.

Evaluación clínica

Revisamos su diagnóstico, informes y atención actual para confirmar si existe un enfoque pertinente.

Tratamiento definido

Su propuesta identifica el tratamiento, la preparación y las citas propuestas para su situación.

Seguimiento planificado

Las citas de seguimiento y el control de la recuperación se incluyen en su propuesta para que sepa qué esperar.

Un total por escrito

Una propuesta escrita detalla el precio completo del tratamiento. Alojamiento, apoyo y servicios opcionales por separado.

Obtenga una evaluación gratuita